While qPB-engineered CAR-T cells derived from healthy donors generally exhibited CD8 enrichment, cancer patient-derived CAR-T cells had a balanced CD8/CD4 CAR-T ratio (Fig 6). The gene discussed is CD4; the disease is cancer.